- On the other hand Minister Modise is taking pharmaceuticals head-on
- The BDP wants a full investigation into Minister Moswaane’s claims
Botswana’s Parliament has been rocked by grave allegations that threaten the very foundations of the country’s public health system. Ignatius Moswaane, Member of Parliament for Francistown West and Assistant Minister of Local Government and Traditional Affairs, dropped a political bombshell, accusing the government of dispensing expired and substandard medicines to children and vulnerable patients. His claims, which allege that between July 2023 and July 2024 children received “deadly drugs” and that those suffering from chronic illnesses like hypertension and HIV/AIDS were given compromised medication, have sent shockwaves through Botswana’s political and healthcare landscapes.
The implications of these accusations are grave. Moswaane alleges that these unauthorized and potentially harmful medicines slipped into Botswana’s hospitals without oversight from the Botswana Medicines Regulatory Authority (BoMRA), the agency tasked with safeguarding medicine quality, efficacy, and safety. This breach, if true, would represent a catastrophic failure of regulatory mechanisms meant to protect the population from harmful pharmaceuticals. BoMRA, which plays a critical role in quality control, has yet to issue a public statement regarding these allegations, but its involvement will be pivotal in any ensuing investigation.
The political fallout has been immediate. The Botswana Democratic Party (BDP), which held power before the current government, has condemned the allegations as unfounded and damaging. Yet, rather than dismissing them outright, the BDP has directed its members to push for a parliamentary inquiry through the establishment of a select committee. This move underscores the seriousness with which the party views the potential breach of public trust and the need for transparency and accountability.
At the heart of this scandal is the Ministry of Health, led by Dr. Steven Modise, who has already been under scrutiny for procurement challenges that have contributed to medicine shortages and supply chain issues. The ministry’s procurement practices have come under fire recently, with reports suggesting inflated costs and halted tender processes, which further complicate the narrative around medicine availability and quality. Dr. Modise has publicly stated that the ministry will not tolerate middlemen inflating medicine prices, revealing a staggering price gap where medications costing the private sector P200 are charged to the government at P4,900, highlighting systemic inefficiencies and potential corruption risks.
This controversy emerges amid a broader healthcare crisis in Botswana. The country declared a public health emergency in 2025 after its national medical supply chain collapsed, resulting in critical shortages of essential medicines and forcing hospitals to suspend non-urgent surgeries. The downturn in diamond revenues, a major source of government funding, has intensified financial strain on the healthcare system, fueling concerns over the sustainability of medicine procurement and distribution.
The allegations also strike at a sensitive nerve given Botswana’s long-standing commitment to combating HIV/AIDS. The country has invested heavily in treatment programs and has been lauded for its efforts, including pioneering the use of dolutegravir as first-line therapy. Any compromise in medication quality could have devastating effects on patient outcomes and public trust in these programs. For a nation with an adult HIV prevalence rate nearing 25 percent, maintaining the integrity of antiretroviral therapy is not just a medical priority but a social imperative.
The Speaker of the National Assembly, Dithapelo Keorapetse, has described the claims as “weighty and serious” and has called on Moswaane to submit evidence by Monday to substantiate his allegations. This procedural move reflects the delicate balance parliament must maintain between ensuring accountability and preventing the spread of unsubstantiated claims that could incite public panic or political instability.
Observers note that if evidence supports the allegations, the fallout could extend beyond political embarrassment to criminal investigations and administrative overhauls. Ministries involved in regulatory oversight, procurement, and even civil aviation, implicated due to alleged smuggling of medicines, could face intense scrutiny. Conversely, if the claims lack substantiation, it raises questions about the motivations behind such serious accusations and their potential to undermine public confidence in government institutions.
Healthcare professionals and citizens alike are watching closely. The notion that expired or counterfeit drugs could have been administered to children and chronically ill patients challenges the very trust that underpins the public health system. Botswana’s healthcare infrastructure, while praised for universal access and significant strides in disease management, has not been immune from challenges linked to funding, governance, and quality assurance.
The unfolding investigation will test its commitment to human rights, transparency, and the health security of its people. With parliamentary motions underway and public anxiety mounting, there is a pressing need for clear communication and decisive action. The Ministry of Health must demonstrate leadership and accountability, ensuring that medicine procurement and regulatory systems are fortified against future breaches.
As this story develops, the eyes of Botswana, and indeed the broader international community, are on the nation’s response. The integrity of Botswana’s healthcare system, the health of its children, and the confidence of its citizens hang in the balance. Whether these allegations will expose systemic failings or prove unfounded remains to be seen, but the urgency of addressing them could not be clearer. This moment demands that Botswana’s leaders put health before politics and safeguard the rights and lives of all their people.